AIIPDD · AI-driven IP Intelligence Engine for Drug Discovery

Today, new drug development on average costs $2.6 billion and takes 10-14 years. But, for example, the global health emergencyover the spread of the deadly new coronavirus, is proving to be a crucial real-life test case for industry to aim dramatically reduce thetime it takes to create new vaccines and drugs to combat emerging pandemics. While AI technologies help to identify thousands ofnew molecules that could be turned into potential medicines, it`s crucial to quickly establish the novelty of the most promisingcandidates. Therefore, more than 135 million patents, 70 million journal articles, and 4 billion web pages are published creating a vastcorpus, Big Data of information that potentially needs to be searched to establish, for example, the novelty of a product, the state ofthe art in the field of interest or the variety of components within complex compositions. Besides, 88% of the Big Data is unstructured(in form of texts) and its volume increases by a staggering 62% annually, according to IDC. It leads to the main challenge: there issimply way too much data for any human to read, analyze and understand.Semantic Intelligence develops an AI-driven IP intelligence Engine enabling users to search, analyze and extract complex knowledgeon chemical-biological interactions in patents. Our proprietary State-of-the-art technology combines Natural Language Processing +Machine Learning + Full linguistic data analysis + Chemical structure processing and Image Recognition, delivering novel ways byintegrating two languages: chemical structure and words, into a single semantic meaning. The target audience for this solution issmall and medium-sized life science companies, which currently have limitations in accessing expensive biochemistry databases. Weare aiming to disrupt the life science industry by delivering a low-cost solution to enable small & medium market players to create value by protecting their IP.